Icotinib: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Icotinib''' is a | {{Short description|Overview of the drug Icotinib}} | ||
{{Drugbox | |||
| verifiedrevid = 123456789 | |||
| image = Icotinib.svg | |||
| image_size = 200px | |||
| image_alt = Structural formula of Icotinib | |||
| image_caption = Chemical structure of Icotinib | |||
}} | |||
'''Icotinib''' is a [[tyrosine kinase inhibitor]] used in the treatment of [[non-small cell lung cancer]] (NSCLC). It is an oral medication that targets the [[epidermal growth factor receptor]] (EGFR), which is often overexpressed in certain types of cancer cells. | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Icotinib | Icotinib functions by inhibiting the [[epidermal growth factor receptor]] (EGFR) tyrosine kinase. EGFR is a transmembrane receptor that, when activated by its natural ligands, triggers a cascade of downstream signaling pathways promoting cell proliferation and survival. In many cancers, EGFR is overexpressed or mutated, leading to uncontrolled cell growth. By blocking EGFR, icotinib disrupts these signaling pathways, thereby inhibiting tumor growth and inducing apoptosis in cancer cells. | ||
==Clinical Use== | ==Clinical Use== | ||
Icotinib is | Icotinib is primarily indicated for the treatment of [[non-small cell lung cancer]] (NSCLC) in patients who have specific mutations in the EGFR gene. It is particularly effective in patients with [[exon 19 deletions]] or [[exon 21 L858R substitution mutations]]. | ||
== | ==Administration== | ||
The | Icotinib is administered orally, typically in the form of tablets. The standard dosage regimen involves taking the medication three times daily, with or without food. It is important for patients to adhere to the prescribed schedule to maintain effective drug levels in the body. | ||
== | ==Side Effects== | ||
Common side effects of icotinib include skin rash, diarrhea, and fatigue. These side effects are generally mild to moderate in severity. More serious adverse effects can occur, such as interstitial lung disease, which requires immediate medical attention. | |||
==Comparison with Other EGFR Inhibitors== | ==Comparison with Other EGFR Inhibitors== | ||
Icotinib is one of several EGFR inhibitors available for the treatment of NSCLC. | Icotinib is one of several [[EGFR inhibitors]] available for the treatment of NSCLC. Other drugs in this class include [[gefitinib]] and [[erlotinib]]. While all these medications target the same receptor, they may differ in terms of efficacy, side effect profiles, and patient response. Icotinib has been shown to have a similar efficacy to gefitinib in clinical trials, with some studies suggesting a more favorable side effect profile. | ||
== | ==Research and Development== | ||
Ongoing research is focused on identifying biomarkers that predict response to icotinib, as well as exploring its use in combination with other therapies. Studies are also investigating its potential application in other types of cancer beyond NSCLC. | |||
[[Category: | ==Related pages== | ||
* [[Non-small cell lung cancer]] | |||
* [[Tyrosine kinase inhibitor]] | |||
* [[Epidermal growth factor receptor]] | |||
* [[Gefitinib]] | |||
* [[Erlotinib]] | |||
[[Category:Antineoplastic drugs]] | |||
[[Category:Tyrosine kinase inhibitors]] | [[Category:Tyrosine kinase inhibitors]] | ||
Revision as of 04:00, 13 February 2025
Overview of the drug Icotinib
| Icotinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Icotinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). It is an oral medication that targets the epidermal growth factor receptor (EGFR), which is often overexpressed in certain types of cancer cells.
Mechanism of Action
Icotinib functions by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR is a transmembrane receptor that, when activated by its natural ligands, triggers a cascade of downstream signaling pathways promoting cell proliferation and survival. In many cancers, EGFR is overexpressed or mutated, leading to uncontrolled cell growth. By blocking EGFR, icotinib disrupts these signaling pathways, thereby inhibiting tumor growth and inducing apoptosis in cancer cells.
Clinical Use
Icotinib is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) in patients who have specific mutations in the EGFR gene. It is particularly effective in patients with exon 19 deletions or exon 21 L858R substitution mutations.
Administration
Icotinib is administered orally, typically in the form of tablets. The standard dosage regimen involves taking the medication three times daily, with or without food. It is important for patients to adhere to the prescribed schedule to maintain effective drug levels in the body.
Side Effects
Common side effects of icotinib include skin rash, diarrhea, and fatigue. These side effects are generally mild to moderate in severity. More serious adverse effects can occur, such as interstitial lung disease, which requires immediate medical attention.
Comparison with Other EGFR Inhibitors
Icotinib is one of several EGFR inhibitors available for the treatment of NSCLC. Other drugs in this class include gefitinib and erlotinib. While all these medications target the same receptor, they may differ in terms of efficacy, side effect profiles, and patient response. Icotinib has been shown to have a similar efficacy to gefitinib in clinical trials, with some studies suggesting a more favorable side effect profile.
Research and Development
Ongoing research is focused on identifying biomarkers that predict response to icotinib, as well as exploring its use in combination with other therapies. Studies are also investigating its potential application in other types of cancer beyond NSCLC.
